Maintain position; do not add capital at current levels. Wait for either confirmed breakout above $207.76 or pullback to $180-185 zone for better risk/reward entry.

• PEG of 2.29 means investors are paying $2.29 per dollar of growth, expensive by historical measures regardless of smoke-free re-rating thesis
• 3.35% dividend yield versus 5% Treasury yield creates unfavorable opportunity cost for income investors; historical pattern shows dividend multiples compress when risk-free rates rise
• FCF payout ratio sits at 81% with Q2 2026 FCF of $5.1 billion (one quarter) versus full-year FCF of $10-11 billion; Q1 was actually negative FCF
• Technical setup shows lower-high pattern from $207.76 to $194.86 (not closed above on a sustained basis); MACD histogram at +0.10 is barely positive; RSI at 53.66 is neutral
• Risk/reward for new capital at $191.50 is unfavorable: $5.08 risk to $13 upside (1:2.6 ratio) with stock having already given back the $207.76 move once
• Downside scenario to $175 (200 SMA) represents 8.5% decline versus 8-15% upside framing; asymmetric risk not in favor of new capital
• All positive catalysts (dividend hike September 21, FDA news, defensive rotation, Q3 earnings) are already announced and priced in; optimal entry was $185 three weeks ago, not $191.50 today
• 19 consecutive years of dividend growth creates essentially impossible-to-break commitment, leaving FCF cushion non-discretionary

→ vs aggressive: PEG of 2.29 is not a 'stale framework' but a valid signal that investors are paying $2.29 per dollar of growth; re-rating events often fail to materialize and this narrative justifies buying at peak conviction

→ vs aggressive: Comparing 3.35% yield to 5% Treasuries is not 'bond math on equity' but correct opportunity cost analysis; when long-end yields hit generational highs, history shows dividend multiples compress structurally

→ vs aggressive: Q2 2026 FCF of $5.1 billion is cherry-picked from one strong quarter; trailing payout ratio of 81% leaves thin cushion, especially given Q1 was negative FCF

→ vs aggressive: Lower-high pattern from $207.76 to $194.86 is distribution, not 'textbook digestion'; MACD at +0.10 and RSI at 53.66 indicate equilibrium, not launch position

→ vs aggressive: Risk/reward of entry at $194.86 with stop at $189.88 (1:2.6) assumes breakout holds when stock has already failed once; 'coiled spring' narrative ignores confirmed technical damage

→ vs aggressive: Catalyst stack is already priced in at $191.50; dividend hike, FDA news, and defensive rotation were all telegraphed; correct entry was $185 three weeks ago, not current levels

→ vs aggressive: Framing downside as '5% drawdown' while upside is 10-15% ignores realistic base case of $175 (200 SMA, 8.5% down) which is not a tail risk given 4.5% ATR

HOLD with active conditional monitoring: maintain current position, do not add at $191.50, be prepared to add on $194.86 breakout with volume or $180-185 pullback with technical support confirmation, trim on close below $182.83 on volume. Position valid while 50 SMA at $189.88 holds.

• Lower-high pattern from $207.76 to $194.86 in place for six weeks, not yet refuted by price action
• MACD histogram at +0.10 is barely positive, not aggressive momentum confirmation
• RSI at 53.66 indicates equilibrium between buyers and sellers
• Dividend hike of 8.8% announced Sept 21 raises implied run-rate yield to approximately 3.45%
• 81% FCF payout ratio creates thin cushion; Q2 FCF $5.1 billion is the supporting baseline
• PM up 28% from June low, making current levels potentially already reflect catalyst stack
• 0.40 beta confirms defensive characteristics with structural dividend floor
• 19-year dividend growth streak supports long-term thesis
• Add at $191.50: 8-10% upside to $207, 4-5% downside risk with no correction confirmation
• Add at $180-185: 12-15% upside to $207, 3-4% downside with greater entry cushion
• Breakout above $194.86 on volume provides confirmation but entry closer to resistance
• 50 SMA at $189.88 is critical support level; failure requires HOLD thesis reassessment
• 200 SMA at $174.94 represents deeper support if $182.83 breaks on volume

→ vs aggressive: Catalysts already priced in (dividend hike Sept 21, FDA streamlining, 28% rally from June low); framing momentum as fundamental catalyst analysis

→ vs aggressive: Lower-high pattern from $207.76 to $194.86 over six weeks not refuted, just asserted away; MACD histogram at +0.10 is barely positive, not a coiled spring

→ vs aggressive: Extrapolating Q2 $5.1 billion FCF as new baseline is the kind of extrapolation that gets blown up in defensive names

→ vs conservative: Bond math on equity income overstates compression risk; current 3.35% yield snapshot ignores 7.2% historical dividend growth and 8.8% recent hike

→ vs conservative: Passive patience has opportunity cost when yield reinvestment at 3.35% rising yield is doing real work in a 0.40 beta name with 19-year growth streak

→ vs conservative: Breakout above $207.76 is same trigger as aggressive analyst, just with higher confirmation bar, so conservative case collapses to waiting for 5% pullback that may never come